Safety and Efficacy Evaluations for Vaginal and Rectal Use of BufferGel in the Macaque Model

Overview

Journal Sex Transm Dis

Specialty Infectious Diseases

Date 2004 Apr 27

PMID 15107631

Citations 20

Authors

D L Patton

Y C Sweeney

P K Cummings

L Meyn

L K Rabe

S L Hillier

Affiliations

Soon will be listed here.

Abstract

Background: The nonhuman primate model allows for safety and efficacy testing of topical microbicide products.

Goal: The goal of this study was to evaluate the safety and efficacy of vaginal and rectal applications of BufferGel (ReProtect, Inc.).

Study Design: The safety of repeated product applications was evaluated by microflora, pH, vaginal colposcopy, and rectal lavage. To test efficacy in preventing chlamydia, infection was documented by culture and nucleic acid amplification tests.

Results: Repeated vaginal or rectal applications of BufferGel were not associated with significant changes in microflora. BufferGel use had a transient acidifying effect on vaginal and rectal pH. Colposcopic observations remained relatively normal in all test animals. A slightly increased incidence of epithelial desquamation was noted after rectal product use compared with the control group. BufferGel did not prevent cervical or rectal chlamydial infection.

Conclusion: BufferGel has an acceptable safety profile after repeated vaginal and rectal use, but does not prevent chlamydial infection in the macaque models.

Citing Articles

Next generation 3D-printed intravaginal ring for prevention of HIV and unintended pregnancy.

Young I, Srinivasan P, Shrivastava R, Janusziewicz R, Thorson A, Cottrell M Biomaterials. 2023; 301:122260.

PMID: 37549505 PMC: 11537264. DOI: 10.1016/j.biomaterials.2023.122260.

Impact of the griffithsin anti-HIV microbicide and placebo gels on the rectal mucosal proteome and microbiome in non-human primates.

Girard L, Birse K, Holm J, Gajer P, Humphrys M, Garber D Sci Rep. 2018; 8(1):8059.

PMID: 29795295 PMC: 5966460. DOI: 10.1038/s41598-018-26313-8.

Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge.

Sholukh A, Watkins J, Vyas H, Gupta S, Lakhashe S, Thorat S Vaccine. 2015; 33(17):2086-95.

PMID: 25769884 PMC: 4411954. DOI: 10.1016/j.vaccine.2015.02.020.

HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women.

Guffey M, Richardson B, Husnik M, Makanani B, Chilongozi D, Yu E Sex Transm Infect. 2014; 90(5):363-9.

PMID: 24898857 PMC: 4278566. DOI: 10.1136/sextrans-2014-051537.

Rectal pre-exposure prophylaxis (PrEP).

Rohan L, Yang H, Wang L Antiviral Res. 2013; 100 Suppl:S17-24.

PMID: 24188705 PMC: 3896093. DOI: 10.1016/j.antiviral.2013.09.023.